会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • Stability Drying
    • 稳定性干燥
    • US20100120014A1
    • 2010-05-13
    • US12462855
    • 2009-08-10
    • Victor Bronshtein
    • Victor Bronshtein
    • C12N9/96C12N1/04C12N5/02A01N1/00
    • A01N1/02A01N1/0231A01N1/0284A61K9/1652A61K35/18A61K35/52C12N1/04C12N7/00C12N9/00C12N11/04C12N2760/20151
    • A method of formulating high ambient temperature (room temperature and above) stable biologics (biologically active macromolecules, enzymes, serums, vaccines, viruses, pesticides, drug delivery systems, liposomes, cells suspensions, sperm, erythrocytes, other blood cells, stem cells, multicellular tissues, skin, heart valves) including secondary drying comprising at least two steps of stability drying at elevated temperature: 35° C., 40° C., 45° C., 50° C., and higher temperatures. The method could be applied to stabilize biologics encapsulated in alginate gel microspheres for better oral delivery. The method encompasses the following: microspheres are formulated using a cryo-encapsulation procedure comprised of mixing drops of frozen preservation mixture (To form the preservation mixture, biologics are mixed with preservation solutions containing sodium alginate.) with frozen drops of a calcium solution (i.e. calcium gluconate) and subsequent warming to form the gel particles.
    • 制定高环境温度(室温及以上)稳定生物制剂(生物活性大分子,酶,血清,疫苗,病毒,农药,药物递送系统,脂质体,细胞悬浮液,精子,红细胞,其他血细胞,干细胞, 多细胞组织,皮肤,心脏瓣膜),包括二次干燥,其包括在升高的温度下稳定干燥的至少两个步骤:35℃,40℃,45℃,50℃和更高的温度。 该方法可用于稳定包封在藻酸盐凝胶微球中的生物制剂,以更好地口服。 该方法包括以下:使用包含冷冻保存混合物滴的冷冻包封方法配制微球体(将形成保存混合物的生物制品与含藻酸钠的保存溶液混合)与冷冻的钙溶液滴(即 葡萄糖酸钙)并随后升温以形成凝胶颗粒。
    • 8. 发明授权
    • Preservation by vaporization
    • 汽化保存
    • US09469835B2
    • 2016-10-18
    • US11569342
    • 2005-06-01
    • Victor Bronshtein
    • Victor Bronshtein
    • A01N1/02C12N9/04C12N9/96C12N1/04
    • C12N1/04A01N1/0284C12N9/0006C12N9/96
    • Significant research is being done to develop and improve delivery mechanisms for biopharmaceuticals and vaccines, including pulmonary (inhalation), nasal, transdermal, and oral alternatives. Market projections indicate that the delivery of proteins and vaccines by inhalation and oral formulation has become and will continue to be increasingly important. These delivery mechanisms, to be effective, will require better stabilization of the biologicals so that they can maintain potency and effectiveness at ambient temperatures for extended periods of time. The novel Preservation by Vaporization (PBV) Technology described herein provides cost-effective and efficient industrial scale stabilization of proteins, viruses, bacteria, and other sensitive biologicals, thereby allowing a production of products that are not possible to be produced by existing methods. The suggested new PBV process comprises primary drying under vacuum from a partially frozen state (i.e. slush) at near subzero temperatures followed by stability drying at elevated temperatures (i.e., above 40 degrees Celsius). The new suggested method can be performed aseptically in unit doze format (in vials) and/or in bulk format (in trays, bags, or other containers). The drying can be performed as a continuous load process in a manifold vacuum dryer comprising a plurality (e.g., 30) of vacuum chambers attached to a condenser during the drying.
    • 正在进行重大研究,以开发和改进生物制药和疫苗的输送机制,包括肺部(吸入),鼻腔,经皮和口服替代物。 市场预测表明,通过吸入和口服制剂递送蛋白质和疫苗已经并将继续变得越来越重要。 这些传递机制要有效,将需要更好地稳定生物体,使其能够在环境温度下保持长时间的效力和有效性。 本文所述的新型蒸发保存技术(PBV)技术提供了蛋白质,病毒,细菌和其他敏感生物的成本有效和高效的工业规模稳定化,从而允许生产不可能通过现有方法生产的产品。 建议的新的PBV方法包括在几乎零下的温度下从部分冷冻状态(即,冷却)在真空下初次干燥,然后在升高的温度(即高于40摄氏度)下稳定地干燥。 新建议的方法可以在单位打盹格式(小瓶)和/或批量格式(托盘,袋子或其他容器)中无菌地进行。 干燥可以在包括在干燥期间连接到冷凝器的多个(例如,30个)真空室的歧管真空干燥器中作为连续加载过程进行。
    • 10. 发明申请
    • POLYMERIC COMPOSITIONS CONTAINING AMBIENT-TEMPERATURE STABLE BIOPHARMACEUTICALS & METHODS FOR FORMULATION THEREOF
    • 包含环境温度稳定生物技术的聚合物组合物及其制备方法
    • US20140356408A1
    • 2014-12-04
    • US14292809
    • 2014-05-30
    • Victor Bronshtein
    • Victor Bronshtein
    • A61L26/00A61K35/74
    • A61K9/0021A61K35/741Y02A50/387Y02A50/406Y02A50/465Y02A50/471Y02A50/483
    • Biopharmaceuticals, such as vaccine agents and probiotics, are encapsulated in carbohydrate-glass particles and embedded in an amorphous polymer substrate to produce polymeric compositions containing ambient-temperature stable biopharmaceuticals for syringeless administration to patients such as via dissolvable films, micro-needle patches and similar medical delivery devices. The amorphous polymer substrate is soluble in both water and volatile organic solvents, yet the carbohydrate-glass particles are insoluble in organic solvents. A method for formulation of the polymeric compositions containing ambient-temperature stable biopharmaceuticals includes combining biopharmaceuticals encapsulated in carbohydrate-glass particles with polymer in organic solvent and evaporating the organic solvent to yield a water soluble polymeric composition containing ambient-temperature stable biopharmaceuticals.
    • 诸如疫苗剂和益生菌之类的生物药物被包封在碳水化合物 - 玻璃颗粒中并且嵌入到无定形聚合物基质中以产生含有环境温度稳定的生物药物的聚合物组合物,用于向患者注射无菌施用,例如通过可溶解的膜,微针贴片和类似物 医疗输送装置 无定形聚合物基材可溶于水和挥发性有机溶剂,但碳水化合物玻璃颗粒不溶于有机溶剂。 制备含有环境温度稳定的生物药物的聚合物组合物的方法包括将包封在碳水化合物玻璃颗粒中的生物药物与聚合物结合在有机溶剂中并蒸发有机溶剂以产生含有环境温度稳定的生物药物的水溶性聚合物组合物。